Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AC Immune (ACIU) Operating Expenses: 2015-2025

Historic Operating Expenses for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to -$21.4 million.

  • AC Immune's Operating Expenses fell 1.70% to -$21.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.4 million, marking a year-over-year increase of 37.64%. This contributed to the annual value of $91.0 million for FY2024, which is 17.92% up from last year.
  • AC Immune's Operating Expenses amounted to -$21.4 million in Q3 2025, which was up 14.46% from -$25.0 million recorded in Q2 2025.
  • In the past 5 years, AC Immune's Operating Expenses registered a high of $159.4 million during Q4 2024, and its lowest value of -$25.0 million during Q2 2025.
  • For the 3-year period, AC Immune's Operating Expenses averaged around $9.1 million, with its median value being -$21.0 million (2024).
  • Data for AC Immune's Operating Expenses shows a peak YoY increase of 19.29% (in 2024) and a maximum YoY decrease of 26.27% (in 2024) over the last 5 years.
  • AC Immune's Operating Expenses (Quarterly) stood at $146.7 million in 2021, then dropped by 7.38% to $135.8 million in 2022, then fell by 1.65% to $133.6 million in 2023, then climbed by 19.29% to $159.4 million in 2024, then dropped by 1.70% to -$21.4 million in 2025.
  • Its Operating Expenses was -$21.4 million in Q3 2025, compared to -$25.0 million in Q2 2025 and -$22.6 million in Q1 2025.